Phase I/II trial of NSI 566 for the treatment of motor deficits caused by ischaemic stroke

Trial Profile

Phase I/II trial of NSI 566 for the treatment of motor deficits caused by ischaemic stroke

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs NSI 566 (Primary)
  • Indications Paralysis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Neuralstem China
  • Most Recent Events

    • 27 Jan 2016 According to a Neuralstem media release, preliminary data from the first cohort of patients was presented at the Phacilitate Cell & Gene Therapy World Conference, Washington D.C. The media release also states that dosing of the second cohort has been completed.
    • 09 Nov 2015 According to a Neuralstem media release, the phase II portion of this study is expected to commence in 2016.
    • 20 Jan 2014 Planned number of patients changed to 118.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top